Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 11/20 | 0.70 |
| ▸ | NPC1 | O15118 | 10/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.70 |
| ▸ | LMNA | P02545 | 5/20 | 0.70 |
| ▸ | TP53 | P04637 | 4/20 | 0.70 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.70 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.70 |
| ▸ | RELA | Q04206 | 2/20 | 0.70 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 5/20 | 0.68 |
| ▸ | MEN1 | O00255 | 4/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.68 |
| ▸ | HPGD | P15428 | 3/20 | 0.68 |
| ▸ | TSHR | P16473 | 3/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.66 |
| ▸ | PKM | P14618 | 1/20 | 0.66 |
| ▸ | THRB | P10828 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.64 |
| ▸ | USP2 | O75604 | 3/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7718014 | 0.83 | RAB9A (0.70) | RAB9ANPC1SMN1; SMN2LMNATP53 | |
| SCHEMBL22804219 | 0.83 | RAB9A (0.70) | RAB9ANPC1SMN1; SMN2LMNATP53 | |
| SCHEMBL18180861 | 0.83 | RAB9A (0.70) | RAB9ANPC1SMN1; SMN2LMNATP53 | |
| SCHEMBL3642839 | 0.83 | MAPT (0.88) | RAB9ANPC1SMN1; SMN2LMNATP53 | |
| SCHEMBL31337431 | 0.81 | MAPT (0.70) | RAB9ANPC1SMN1; SMN2LMNATP53 | |
| SCHEMBL7159563 | 0.79 | ALDH1A1 (1.00) | RAB9ASMN1; SMN2LMNAMAPTMEN1 | |
| SCHEMBL12793737 | 0.78 | MEN1 (0.64) | RAB9ANPC1SMN1; SMN2LMNATP53 | |
| SCHEMBL20370637 | 0.77 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2LMNATP53 | |
| SCHEMBL7155752 | 0.76 | ALDH1A1 (0.76) | RAB9ANPC1SMN1; SMN2LMNATP53 | |
| SCHEMBL1687871 | 0.76 | HDAC3 (0.64) | RAB9ANPC1SMN1; SMN2LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025022031-A1 | NEW DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (ES) | 2025-01-30 | — | — | WO | disclosed |
| EP-2527326-B1 | Novel compounds having 4-pyridylalkylthio group as substituent | SANTEN PHARMACEUTICAL CO LTD (JP) | 2014-10-08 | — | — | EP | disclosed |
| EP-2527326-B1 | Novel compounds having 4-pyridylalkylthio group as substituent | SANTEN PHARMACEUTICAL CO LTD (JP) | 2014-10-08 | — | — | EP | disclosed |
| EP-1602647-B1 | NOVEL COMPOUND HAVING 4-PYRIDYLALKYLTHIO GROUP AS SUBSTITUENT | SANTEN PHARMACEUTICAL CO LTD (JP) | 2013-10-16 | — | — | EP | disclosed |
| EP-1602647-B1 | NOVEL COMPOUND HAVING 4-PYRIDYLALKYLTHIO GROUP AS SUBSTITUENT | SANTEN PHARMACEUTICAL CO LTD (JP) | 2013-10-16 | — | — | EP | disclosed |
| US-8518973-B2 | Compounds having 4-pyridylalkylthio group as a substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-08-27 | — | — | US | disclosed |
| US-8518973-B2 | Compounds having 4-pyridylalkylthio group as a substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-08-27 | — | — | US | disclosed |
| US-8518973-B2 | Compounds having 4-pyridylalkylthio group as a substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-08-27 | — | — | US | disclosed |
| US-20120202817-A1 | COMPOUNDS HAVING 4-PYRIDYLALKYLTHIO GROUP AS A SUBSTITUENT | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-08-09 | — | — | US | disclosed |
| US-20120202817-A1 | COMPOUNDS HAVING 4-PYRIDYLALKYLTHIO GROUP AS A SUBSTITUENT | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-08-09 | — | — | US | disclosed |
| US-20060194836-A1 | Novel compounds having 4-pyridylalkylthio group as substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2006-08-31 | — | — | US | disclosed |
| EP-1602647-A1 | NOVEL COMPOUND HAVING 4-PYRIDYLALKYLTHIO GROUP AS SUBSTITUENT | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2005-12-07 | — | — | EP | disclosed |
| US-20030232841-A1 | Heterocyclic carboxamides | PFIZER INC | 2003-12-18 | — | — | US | disclosed |
| US-6602874-B2 | 5-(2-(4-methylpiperazin-1-yl)-phenyl)- furan-2-carboxylic acid 4-chlorobenzylamide, for example; treating or preventing migraine, depression and other disorders for which a 5-HT1, agonist or antagonist is indicated | PFIZER INC. | 2003-08-05 | — | — | US | disclosed |
| US-6537995-B2 | Selective serotonin receptor agonists and antagonists used to treat migraines, depression, anxiety and schizophrenia; sertraline | PFIZER INC. | 2003-03-25 | — | — | US | disclosed |
| EP-0957099-B1 | Heterocyclic carboxamides | PFIZER PROD INC (US) | 2002-11-20 | — | — | EP | disclosed |
| US-20020002168-A1 | Heterocyclic carboxamides | HOWARD HARRY R (US) | 2002-01-03 | — | — | US | disclosed |
| US-20010041705-A1 | Heterocyclic carboxamides | HOWARD HARRY R (US) | 2001-11-15 | — | — | US | disclosed |
| US-6277852-B1 | FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | PFIZER INC | 2001-08-21 | — | — | US | disclosed |
| EP-0957099-A2 | Heterocyclic carboxamides | Pfizer Products Inc. (US) | 1999-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194836-A1 | Novel compounds having 4-pyridylalkylthio group as substituent | FLT4, FLT1, KDR | RAB9A 1196/4885NPC1 1632/4885SMN1; SMN2 4686/4885 |
| US-20120202817-A1 | COMPOUNDS HAVING 4-PYRIDYLALKYLTHIO GROUP AS A SUBSTITUENT | FLT1, PYM1, FLT4 | RAB9A 1301/4885NPC1 1791/4885SMN1; SMN2 3840/4885 |
| US-20020002168-A1 | Heterocyclic carboxamides | HTR1A, HTR1D, NPY1R | RAB9A 2435/4885NPC1 2453/4885SMN1; SMN2 2548/4885 |
| US-20030232841-A1 | Heterocyclic carboxamides | HTR1A, HTR1D, NPY1R | RAB9A 2435/4885NPC1 2453/4885SMN1; SMN2 2548/4885 |
| US-20010041705-A1 | Heterocyclic carboxamides | HTR1A, HTR1D, NPY1R | RAB9A 2435/4885NPC1 2453/4885SMN1; SMN2 2548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.